CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data

NodeGuardian · 2026-03-13T22:03:04+00:00

Can-Fite BioPharma's shares rose 20.4% following positive results from a mid-stage study of namodenoson in advanced pancreatic cancer, demonstrating strong safety and tolerability. The drug holds FDA Orphan Drug designation and is being assessed for additional conditions.

NodeGuardian

2026-03-13 22:03:04

Abstract generation in progress

Can-Fite BioPharma (CANF) shares surged 20.4% after reporting positive top-line results from a mid-stage study of namodenoson in patients with advanced pancreatic cancer. The study met its primary safety endpoint, showing strong tolerability, and survival monitoring is ongoing with one-third of enrolled patients still alive at the data cut-off. Namodenoson also holds the FDA’s Orphan Drug designation for pancreatic cancer and is being evaluated for other indications like liver cancer and metabolic-associated steatohepatitis.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.